JP2024528052A5 - - Google Patents
Info
- Publication number
- JP2024528052A5 JP2024528052A5 JP2024505255A JP2024505255A JP2024528052A5 JP 2024528052 A5 JP2024528052 A5 JP 2024528052A5 JP 2024505255 A JP2024505255 A JP 2024505255A JP 2024505255 A JP2024505255 A JP 2024505255A JP 2024528052 A5 JP2024528052 A5 JP 2024528052A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid molecule
- cancer
- isolated nucleic
- molecule according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163227115P | 2021-07-29 | 2021-07-29 | |
| US63/227,115 | 2021-07-29 | ||
| US202263306862P | 2022-02-04 | 2022-02-04 | |
| US63/306,862 | 2022-02-04 | ||
| PCT/US2022/038640 WO2023009700A2 (en) | 2021-07-29 | 2022-07-28 | Car-expressing immune cells that specifically target mesothelin and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024528052A JP2024528052A (ja) | 2024-07-26 |
| JP2024528052A5 true JP2024528052A5 (cg-RX-API-DMAC10.html) | 2025-07-14 |
Family
ID=85088244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024505255A Pending JP2024528052A (ja) | 2021-07-29 | 2022-07-28 | メソテリンを特異的に標的とするｃａｒ発現免疫細胞及びその使用 |
Country Status (11)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202190624A1 (ru) * | 2018-08-31 | 2021-06-09 | Нойл-Иммьюн Байотек, Инк. | Car-экспрессирующие т-клетки и car-экспрессирующий вектор |
| JP2026518850A (ja) | 2023-04-27 | 2026-06-10 | 武田薬品工業株式会社 | Ｃｄ５６＋／ｃｄ３－細胞の増殖方法 |
| CN119101166A (zh) * | 2023-06-08 | 2024-12-10 | 博生吉医药科技(苏州)有限公司 | B7-H3嵌合抗原受体修饰的Vδ1 T细胞及其应用 |
| JPWO2025094915A1 (cg-RX-API-DMAC10.html) | 2023-10-30 | 2025-05-08 | ||
| WO2025140683A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京鼎成肽源生物技术有限公司 | 表达趋化因子10和白介素15的工程化免疫细胞 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
| CN108728458B (zh) * | 2017-04-21 | 2021-11-16 | 上海恒润达生生物科技股份有限公司 | 靶向mesothelin的嵌合抗原受体并联合表达IL-15的方法和用途 |
| PL3618842T3 (pl) * | 2017-05-01 | 2024-02-19 | Juno Therapeutics, Inc. | Kombinacja terapii komórkowej i związku immunomodulującego |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
| MX428412B (es) * | 2017-12-24 | 2025-11-13 | Noile Immune Biotech Inc | Celula inmunocompetente que expresa una molecula de superficie celular que reconoce especificamente la mesotelina humana, il-7 y ccl19 |
| WO2019160956A1 (en) * | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| EA202190624A1 (ru) | 2018-08-31 | 2021-06-09 | Нойл-Иммьюн Байотек, Инк. | Car-экспрессирующие т-клетки и car-экспрессирующий вектор |
-
2022
- 2022-07-28 WO PCT/US2022/038640 patent/WO2023009700A2/en not_active Ceased
- 2022-07-28 EP EP22850304.1A patent/EP4377355A4/en active Pending
- 2022-07-28 CA CA3227745A patent/CA3227745A1/en active Pending
- 2022-07-28 MX MX2024001364A patent/MX2024001364A/es unknown
- 2022-07-28 AU AU2022316980A patent/AU2022316980A1/en active Pending
- 2022-07-28 IL IL309914A patent/IL309914A/en unknown
- 2022-07-28 TW TW111128457A patent/TW202313979A/zh unknown
- 2022-07-28 KR KR1020247003396A patent/KR20240038723A/ko active Pending
- 2022-07-28 JP JP2024505255A patent/JP2024528052A/ja active Pending
- 2022-07-28 US US18/292,574 patent/US20240374721A1/en active Pending
-
2024
- 2024-02-13 CO CONC2024/0001484A patent/CO2024001484A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250034244A1 (en) | Bicistronic chimeric antigen receptors and their uses | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| You et al. | Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells | |
| JP6426713B2 (ja) | Ｇｐｃ３キメラ抗原受容体蛋白質をコードする核酸及びｇｐｃ３キメラ抗原受容体蛋白質を発現するｔリンパ球 | |
| JP7475088B2 (ja) | ヒトメソセリンを特異的に認識する細胞表面分子、ｉｌ－７、及びｃｃｌ１９を発現する免疫担当細胞 | |
| US12492252B2 (en) | Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibody | |
| CN107312091A (zh) | 靶向人cd19抗原的人源化单克隆抗体 | |
| WO2017219936A1 (zh) | 一种高效稳定表达激活型抗体的car-t细胞及其用途 | |
| CN108367068A (zh) | 用于治疗白血病的抗-s100a8 | |
| CN115925940B (zh) | 特异性结合cd47的抗体、其重组溶瘤病毒及其用途 | |
| CN114929863B (zh) | 共表达趋化因子受体的免疫效应细胞 | |
| CN111944054A (zh) | 抗bcma的car及其表达载体和应用 | |
| JP2024528029A5 (cg-RX-API-DMAC10.html) | ||
| CN115232217B (zh) | 一种SynNotch结构及其应用 | |
| CN117003897B (zh) | 靶向Claudin18.2的CAR-T细胞及其用途 | |
| CN117903317A (zh) | Trop2靶向的CAR分子、CAR-T细胞及其应用 | |
| CN113549157B (zh) | 双靶向嵌合抗原受体及其应用 | |
| CN111944053A (zh) | 抗bcma的car及其表达载体和应用 | |
| CN114685675A (zh) | 双特异性抗体及其在治疗癌症中的用途 | |
| CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
| Aman et al. | The broad spectrum of cancer and immunotherapy: achievements and limitations | |
| Esmaeilzadeh et al. | Chimeric antigen receptor (CAR) T Cell immunotherapy for solid tumors | |
| WO2022033483A1 (zh) | 多功能的免疫效应细胞及其应用 | |
| KR102809807B1 (ko) | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 | |
| CN120882754A (zh) | 用淋巴毒素β受体激动剂治疗癌症的方法 |